Novel Pharmacophores of Connexin43 Based on the “RXP” Series of Cx43-Binding Peptides
- 17 July 2009
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 105 (2), 176-184
- https://doi.org/10.1161/circresaha.109.200576
Abstract
Gap junction pharmacology is a nascent field. Previous studies have identified molecules that enhance intercellular communication, and may offer potential for innovative antiarrhythmic therapy. However, their specific molecular target(s) and mechanism(s) of action remain unknown. Previously, we identified a 34-aa peptide (RXP-E) that binds the carboxyl terminal domain of Cx43 (Cx43CT) and prevents cardiac gap junction closure and action potential propagation block. These results supported the feasibility of a peptide-based pharmacology to Cx43, but the structure of the core active element in RXP-E, an essential step for pharmacological development, remained undefined. Here, we used a combination of molecular modeling, surface plasmon resonance, nuclear magnetic resonance and patch-clamp strategies to define, for the first time, a unique ensemble of pharmacophores that bind Cx43CT and prevent closure of Cx43 channels. Two particular molecules are best representatives of this family: a cyclized heptapeptide (called CyRP-71) and a linear octapeptide of sequence RRNYRRNY. These 2 small compounds offer the first structural platform for the design of Cx43-interacting gap junction openers. Moreover, the structure of these compounds offers an imprint of a region of Cx43CT that is fundamental to gap junction channel function.Keywords
This publication has 22 references indexed in Scilit:
- The Gap Junction Modifier, GAP-134 [(2S,4R)-1-(2-Aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic Acid], Improves Conduction and Reduces Atrial Fibrillation/Flutter in the Canine Sterile Pericarditis ModelJournal of Pharmacology and Experimental Therapeutics, 2009
- RXP-ECirculation Research, 2008
- Pharmacological Modulation of Gap Junction Function with the Novel Compound Rotigaptide: A Promising New Principle for Prevention of ArrhythmiasBasic & Clinical Pharmacology & Toxicology, 2007
- Gap junction modifying antiarrhythmic peptides: Therapeutic potential in atrial fibrillationDrugs of the Future, 2007
- Identification of a Novel Peptide That Interferes With the Chemical Regulation of Connexin43Circulation Research, 2006
- Pharmacology of Cardiovascular Gap JunctionsPublished by S. Karger AG ,2006
- Cardiac Ischemia and Uncoupling: Gap Junctions in Ischemia and InfarctionPublished by S. Karger AG ,2006
- Loss of electrical communication, but not plaque formation, after mutations in the cytoplasmic loop of connexin43Heart Rhythm, 2004
- Structural bases for the chemical regulation of Connexin43 channelsCardiovascular Research, 2004
- Biophysical properties of homomeric and heteromultimeric channels formed by cardiac connexinsCardiovascular Research, 2004